Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.

This article reviews the role and controversies of 5α-reductase inhibitors like finasteride and dutasteride in managing prostate cancer, without presenting new research results.

This study found that dutasteride significantly reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic enlargement compared to placebo.

This study found that protease nexin-1 mRNA is expressed in human dermal papilla cells and is downregulated by dihydrotestosterone in balding scalp, suggesting a role in male-pattern baldness progression.

In this study, researchers found that sesamin, a component of sesamum, modulated the AR-MAPK-Wnt signaling pathway in DHT-stimulated HaCaT keratinocytes, demonstrating potential multi-target activity against molecular events in androgenetic alopecia.

This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.

This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.

The researchers reported that DHT-inducible DKK-1 may play a significant role in DHT-driven balding by inhibiting hair follicle cell growth and promoting apoptosis in androgenetic alopecia.

This study found that finasteride significantly suppresses serum dihydrotestosterone levels at all tested doses in normal male volunteers without significant adverse effects.

Clinical studies reported that finasteride reduces scalp dihydrotestosterone levels and improves hair growth in men with androgenetic alopecia, supporting its role as a treatment option.

This study found that androgen/androgen receptor signaling accelerates premature senescence in dermal papilla cells, highlighting a potential target for treating androgenetic alopecia.

This study found that three months of oral finasteride treatment significantly decreased dihydrotestosterone levels and hair growth in hirsute women without negatively affecting gonadotropin secretion.

This article reviews the pathophysiology, diagnosis, and treatment of androgenic alopecia but reports no new clinical findings.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

This review found that dutasteride is more effective than finasteride in increasing hair count and shaft thickness for androgenetic alopecia in men, with potential for reduced systemic side effects through mesotherapy, although further research is needed on long-term safety and dosage.

This review discusses advances in 5α-reductase inhibitors for treating male androgenetic alopecia and reports no new clinical results.

In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.

This review discusses the role of 5α-reductase in prostate development and BPH, and reports no new clinical results; ongoing trials are exploring dual isozyme inhibitors for improved treatment efficacy.

This article discusses the hair follicle's regenerative cycles and the molecular mechanisms influencing them, emphasizing the need for therapeutic targeting of the "hair cycle clock" to manage hair growth disorders, without reporting new research findings.

This study explains finasteride's high potency and specificity as a mechanism-based inhibitor for treating benign prostatic hyperplasia by detailing its interaction with human type 2 steroid 5α-reductase.

Inflammation may be linked to hair loss, and targeting specific enzymes could help treat it.

This study found that oral finasteride 1 mg/day promotes hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss over two years.

This abstract discusses the unclear role of dihydrotestosterone (DHT) in postembryonic life in marsupials and possibly humans, reporting no new findings.

This study found that oral administration of finasteride to pregnant rats caused dosage-related developmental toxicities, including hypospadias and decreased anogenital distance in male offspring.

This article reviews the molecular mechanisms involved in androgenetic alopecia and the androgen's paradoxical role in hair growth, but reports no new experimental findings.

This review discusses the etio-pathogenetic factors in benign prostatic hyperplasia and their role in the development of lower urinary tract symptoms but reports no new research findings.

This review describes the roles of 5α-reductase isozymes in prostate development and pathology and reports no new clinical results.

This study found that in healthy men, higher levels of free testosterone were associated with a stronger immune response to the influenza vaccine, suggesting androgens may function as immunomodulators rather than strict immunosuppressants.

This review discusses the classifications, diagnostic methods, and treatment strategies for female pattern hair loss, but reports no clinical results.

New treatments for male hypogonadism are effective and should be personalized.